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TOX TOK! Liquid Nicotine Used in
E-Cigarettes can Harm Children
Hafsah Ashfaq - Clinical Pharmacist.
Toddlers are the most vulnerable group to swallow or have contact with a poisonous
substance.
The American Academy of Pediatrics
(AAP) usually offers tips to prevent and
to treat exposures to poison. One of the
most important exposures nowadays
includes E-cigarettes. The refills for
E-cigs, are being sold in hundreds of
different flavors, including flavors and
colors that would be absolutely appealing
to kids. There are many cases reported
globally. Few of the prominent cases are
quoted below:
Case 1: A 1-year-old child died from liquid nicotine poisoning in December
2014— the first such death in the United States. Poison control centers now receive
thousands of calls each year about young children who have been exposed to
vaping-related products.
Case 2: A young child was inadvertently exposed to liquid nicotine [approximately
703mg (35mg/kg)] and collapsed almost immediately. She required aggressive care
including intubation and mechanical ventilation, but recovered within 24 hours
with no permanent sequelae.
Poison Information
Toxicity level

Toxic

Also known as

Nicotine, vape, electronic cigarette, e-cigarette, vape pen

Description

Vaping products are used for their nicotine component.
These products are not meant to be swallowed and not
meant for children to use

Possible symptoms of overdose/
poisoning

Ingesting or chewing tobacco can cause vomiting,
sweating, drowsiness / tiredness, shaking, confusion,
seizures, and even death.
Symptoms typically develop within 30 minutes to 2 hours
after an oral exposure. Symptoms may be immediate after
inhalational exposure.

Fluids And Electrolytes Maintenance
Calculation In Pediatric Patients ......... Page 4
CHOLERA:............................................. Page 6
The 2 Million Dollar Injection..............Page 7

Toxic dose

Retinoic Acid Preparations & their
Differences.............................................. Page 8

A teaspoon of concentrated liquid nicotine can be fatal for
the average 26-pound toddler.

Antidote

There is no specific antidote.
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Treatment: Treatment is primarily supportive and symptomatic. Intravenous fluids can be administered. Persistent
vital sign abnormalities, altered mental status, muscle weakness, and seizures indicate a more severe poisoning. Urine
acidification (while theoretically helpful in enhancing elimination) is not recommended. Also avoid using H2 blocker or
proton pump inhibitor initially because nicotine will be absorbed more easily in an alkaline environment.
Monitoring of patient: No testing is required in patients with mild or no symptoms. Creatine kinase, lactate, urinalysis
should be performed in patients with severe poisonings. The CDC has recently reported pulmonary illnesses associated
with the use of vaping devices (i.e., e-cigarettes) when they are used to aerosolize substances for inhalation(i.e., nicotine
or illicit products). Patients present with respiratory symptoms, including cough, shortness of breath and fatigue. Monitor
pulse oximetry, obtain chest radiograph, CT scan of the chest and pulmonary function tests as indicated.
Take home message: Elders who use e-cigarettes are advised to store the products and any refill materials in childresistant packaging and out of the reach of children.
References:
•
•

www.illinoispoisoncenter.org
www.my.clevelandclinic.org

Monkey Pox FAQs:
Hafsah Ashfaq – Clinical Pharmacist
Monkeypox virus belongs to the Orthopoxvirus genus in the family Poxviridae.
Monkeypox is a rare disease with symptoms that are similar to but milder than
the symptoms of smallpox.

Q: What are the symptoms for Monkey Pox?
A: Fever, malaise, headache, weakness, and pustules on face or vesicles on legs.
Fever before rash and lymphadenopathy are common . These lesions are often
described as painful until the healing phase when they become itchy (crusts).

Q: How is Monkeypox transmitted?
A: Monkeypox is transmitted by symptomatic individuals through close contact
with lesions, bodily fluids, or respiratory secretions and objects that have had
contact with lesion crusts or bodily fluids (e.g., contaminated linens, bandages,
dishes).

Q: What to do for patients with Monkey pox?
A: For patients with monkeypox, isolation precautions should be followed until coverings have fallen off, and a fresh layer of intact
skin has formed. This could take up to 2-4 weeks from the beginning of prodrome.

Q: Is there any Vaccine available in Pakistan for Monkey pox?
A: In Pakistan, currently no vaccine is available for Monkey Pox. Smallpox/monkeypox vaccine (JYNNEOS™) is approved in
US that can help protect against smallpox, monkeypox, and other diseases caused by orthopoxviruses, including vaccinia virus.
JYNNEOS™ is usually administered as a series of 2 injections, 4 weeks apart. People who have received smallpox vaccine in the
past might only need 1 dose
Reference:

www.cdc.gov
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Clinical Understanding of Different Formulations of Tenofovir:
TDF Versus TAF
Quratulain Amir Butt - Pharmacist.
Tenofovir is commercially available as prodrugs, tenofovir
disoproxil fumarate (TDF) & tenofovir alafenamide (TAF).

Tenofovir Disoproxil Fumarate (TDF)
Indication

Treatment of chronic hepatitis B and HIV-1 infection.

Brand name
Dose
Pharmacokinetic
difference

Tenofovir Alafenamide (TAF)

Vireof 300mg

Wymly 25mg

300mg once daily

25mg once daily

TDF has a shorter plasma half-life & rapidly gets converted TAF has a longer plasma half-life & remains stable
to tenofovir while in the plasma, substantially exposing vital
in plasma. It only gets converted to tenofovir
organs to tenofovir.
intracellularly.
A low dose of TAF (25mg) is bioequivalent to 300mg TDF in terms of
plasma levels of tenofovir.

Pharmacodynamic
difference

TAF shows similar clinical efficacy as TDF but with better patient
tolerability & compliance.

Pharmacological
difference

Significant renal & bone toxicity
(Up to 28% or more)

Decreased incidence of renal &
bone toxicity (Up to 5% or less)

Use in pregnancy

US FDA pregnancy category:
Category B

US FDA pregnancy category:
Not assigned yet.

Although TAF use was associated with more weight gain compared to
TDF, both regimens appear safe and effective during pregnancy.
Renal dose adjustment

Hepatic dose adjustment

References:

•

CrCl ≥50 mL/minute: No dosage adjustment
necessary

•

CrCl ≥15 mL/minute: No dosage
adjustment necessary.

•

CrCl 30 to <50 mL/minute: 300 mg every 48
hours or 150 mg once daily

•

CrCl <15 mL/minute: Use is not
recommended.

•

CrCl 10 to <30 mL/minute: 300 mg twice weekly
(every 72 to 96 hours)

•

CrCl <10 mL/minute: Avoid use. If no alternative
therapy is available, then may consider 300 mg every 7
days; use with caution and close monitoring

•

Mild impairment (Child- Pugh class
A): No dosage adjustment necessary.

•

Decompensated cirrhosis (Child-Pugh
class B or C):
Use is not recommended.

No dose adjustment is required.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60616-X/fulltext#seccestitle160
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892670/

Pharmacy Newsletter

4

Fluids And Electrolytes Maintenance Calculation In Pediatric Patients
Mehreen Sohail - Pharmacist.
Maintenance fluid and electrolytes are important due to normal losses from body basal metabolism. Normally, body
metabolism results in two types of by-products: heat and solutes. Heat is involved in basal energy expenditure and is
considered as “insensible water losses” whereas, solutes are usually excreted in the urine which is also known as “urinary
water losses”.
It has been observed that the metabolic rate of a body decreases with increasing age. In other words, neonates generate
more heat and solute from basal metabolism as compared to children and adolescents. Therefore, they require more fluids
and electrolytes per units of body weight and vice versa.
In general, infants become dehydrated faster as compared to older patients. It is because an adolescent can tolerate 12-18
hours without any oral intake. However, an infant needs IV maintenance fluid within 4-6 hours of last feeding.
Several estimates of maintenance fluid needs exist, including surface area method (may underestimate needs/be inaccurate
when weight is less than 10 kg), basal caloric method (most accurate, but less practical), and estimations using weight.
Estimations of maintenance needs using body weight are the most clinically practical, but they may overestimate the
needs.
Estimation of Maintenance Fluid Requirements Using Body Weight for Neonates:
 < 1500 g = 130–150 mL/kg/day
 1500–2000 g = 110–130 mL/kg/day
 Term neonate = 80–150 mL/kg/day
Note: Once the neonate weighs more than around 2–3 kg, the Holliday-Segar method is preferred.
Estimation of Maintenance Fluid Requirements Using Body Weight for Older Infants and Children
HOLLIDAY-SEGAR METHOD
WEIGHT
3 to 10 kg
11 to 20 kg
More than 20 kg
References:

•
•

24-HOUR FLUID

HOURLY RATE

100ml/kg/day

4ml/kg/hr

1000 + 50ml/kg/day for each kg >10

40 + 2 ml/kg/hr for each kg > 10

1500 + 20ml/kg/day for each kg > 20

60 + 1 ml/kg/hr for each kg > 20

Sandra Benavides, Pharm.D, Milap C. Nahata, Pharm.D., FCCP, Pediatric Pharmacotherapy, 2013, United States of America.
Derek S. Wheeler, Pediatric Critical Care Medicine, Second Edition, 2014 Springer London Heidelberg New York Dordrecht.
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BEAT THE HEAT

Some tips to protect yourself against the heat wave
Wear loose, light-weight clothes.
Remember to maintain an adequate level of hydration.
Eat cold and hydrating foods.
When outdoors, seek shade & cover your head. Use umbrellas & hats.
Limit strenuous outdoor activities specially during day times.
Take regular cool showers.
Make sure to get enough rest.

A NEW Warning : FDA recommends thyroid monitoring in babies and young children
who receive injections of iodine-containing contrast media(ICM) for medical imaging.
FDA approved a new warning for the entire class of iodinated contrast media (ICM) injections for children 3 years or
younger. The warning describes the risk of underactive thyroid or a temporary decrease in thyroid hormone levels. These
risks and recommendations pertain to ICM given as an injection through an artery or vein.
What to do?
Babies and young children may need to be monitored by their health
care professionals after receiving ICM. If thyroid dysfunction is
detected, treat as clinically needed to avoid future cognitive and other
developmental disabilities. Most reported cases were transient subclinical
hypothyroidism and did not require treatment.
Who is at Risk?
Few pediatric patients are at an increased risk, including prematurity,
low birthweight or the presence of cardiac or other conditions. Patients
with cardiac conditions may be at greatest risk since they often require
high doses of contrast during invasive cardiac procedures.

Also known as “contrast dye” or “X-ray dye,”
Procedures that use ICM include X-rays of blood
vessels, joints, and organs, and some computed
tomography (CT) scans.
ICM are given as injections into arteries, veins, or
other body cavities; however, the information in this
Drug Safety Communication pertains to ICM given
as an injection through an artery or vein
Common side effects associated with ICM include
flushing in the face, nausea or vomiting, mild
itchiness, and skin rash.
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CHOLERA:

Symptoms

Sehej Hussain – Resident Pharmacist
Cholera is an acute diarrheal illness caused by infection
of the intestine with Vibrio cholera bacteria. Pakistani
health authorities have reported more than 2,000 cholera
cases between 1st January-17th May nationwide amidst
the contaminated water crisis as the country grapples with
a water crisis exacerbated by a brutal heat wave in South
Asia. Emergency relief has been initiated in at-risk areas
including setting up of mobile water tanks to ensure the
population has safe, clean drinking water and setting up
medical tents to treat individuals suffering from cholera
symptoms.

Treatment
Oral rehydration salts can treat up to 80% of cases.

Diarrhea

Dehydration

Nausea &
Vomitings

Prevention

Vaccination

Wash Hands

Intravenous fluids needed for severe cases.
Medications can diminish duration of diarrhea, reduce
volume of rehydration fluids needed, and shorten
duration of the disease.

Maintain Hygiene

Boil water

Supplements: Research suggests that prescribed
supplements may lessen and shorten the duration of
diarrhoea in children affected by cholera.

Wash Vegetables &
Fruits

How to Update Allergy in Patient Profile:
Step 1:
Select Patient==Update
patient

Step 2:
Enter MR #

Step 3:
Tick Generic / Class
Allergies == Select Class Id
& Generic ID
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The 2 Million Dollar Injection
Mariyum Usmani - Resident Pharmacist
Onasemnogene abeparvovec is a gene therapy medication used to treat spinal muscular atrophy (SMA), a serious condition
of the nerves that causes muscle wasting and weakness. It is
indicated for the treatment of pediatric patients less than 2
years of age. It works by replacing the function of the missing
or nonworking SMN1 gene with a new, working copy of an
SMN gene.
Onasemnogene abeparvovec is the first and only gene therapy
approved by the FDA for the treatment of SMA, including
those who are pre-symptomatic at diagnosis.
With a whopping cost of 2.1 million USD (42 Crore PKR) for a
one-dose treatment, onasemnogene abeparvovec is currently the most expensive therapeutic agent in the United States.
On the 12th of May 2022, The Aga Khan University Hospital received Onasemnogene abeparvovec free of cost. On 13th
of May 2022, the medication was successfully administered to a 4-month-old baby girl diagnosed with Spinal Muscular
Atrophy. The child was discharged with a promising prognosis and hope for recovery.
The question arises, is this medication worth its price?
The simple answer, yes.
In the initial clinical trial that was conducted with onasemnogene
abeparvovec, all children were alive at the conclusion of the
study and many were able to sit, roll, crawl, play and some could
even walk! A main study showed that it reduces the need for
artificial ventilation in babies with spinal muscular atrophy. In
a study conducted, 20 out of the 22 babies given onasemnogene
abeparvovec were alive and breathing without a permanent ventilator after 14 months, when normally only a quarter of
untreated patients would survive without needing a ventilator. The study also showed that onasemnogene abeparvovec
can help babies sit unaided for at least 30 seconds, a milestone that is never achieved in untreated babies with severe forms
of SMA.
This level of effectiveness, delivered as a single, one-time therapy, is revolutionary and provides exceptional hope for
families battling SMA.
References
•
•
•

https://www.zolgensma.com
https://www.zolgensma.com/clinical-studies
https://www.fda.gov/vaccines-blood-biologics/zolgensma
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Retinoic Acid Preparations & their Differences
Faqeeha Shakeel- Clinical Pharmacist
Generic name: Cis-Retinoic Acid, Isotretinoin
(Synthetic Retinoic Acid)

Generic name: All-Trans Retinoic Acid
(Natural Retinoic acid)

Strength: 20mg, 10mg

Strength: Capsule = 10 mg,

Indication: Isotretinoin is used primarily in the treatment of acne.
The drug has also been used in several other conditions including
Squamous cell carcinoma, Neuroblastoma.

Indication: Tretinoin is indicated for the induction of remission
in patients with acute promyelocytic leukemia. Tretinoin (orally
or topically) has been studied in the treatment of psoriasis,
dermatoses, and various cancers.

Dose:
Adult:
*Acne: The initial oral dose should be 0.5 to 2 mg/kg/day in 2 divided
doses
Peads:
*Acne: Initial: Oral: 0.5 mg/kg/day in 2 divided doses for 4 weeks,
then increase dose to 1 mg/kg/day in 2 divided doses
*Neuroblastoma: 80 mg/m 2/dose every 12 hours for the last 2 weeks
(14 consecutive days) of a 4-week cycle for 6 cycles.

Dose:
Adult:
Remission induction of acute promyelocytic leukemia: 45 mg/m 2/day
PO (divided twice daily).
Peads:
Remission induction of acute promyelocytic leukemia: 25 mg/m 2/day
in 2 divided doses

ADR reporting Link:
https://vaems.aku.edu/aems_prod/Default.asp

Provide us your Valuable Feedback!
Just drop us an email with subject Newsletter Feedback. Email us at : drug.information@aku.edu
Or fill your feedback through Link: https://forms.gle/FCo9ZuE4CConzFp46
For Formulary assistance visit http://portal.aku.edu/pharmacy/olf.asp or Call 34861504/1506

The Aga Khan University Hospital, Karachi

